At a Takeda-sponsored symposium held at the 51st Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden, on the 14th September 2015, Prof Faiez Zannad of the University of Lorraine and CHU, Vandoeuvre-lès-Nancy, France, provides an overview of results from clinical trials investigating cardiovascular outcomes in patients with Type 2 diabetes treated with oral antidiabetic drugs.
Three trials have assessed the cardiovascular safety of DPP-4 inhibitors, although the EXAMINE study was the only one to actively include acute coronary syndrome patients at high risk of cardiovascular disease.
